The company said it reported fourth-quarter revenues of $11.5 Billion, GAAP EPS of $0.87 and Non-GAAP EPS of $1.70 for Q4 2023, and full-year revenues of $45.0 Billion, GAAP EPS of $3.86 and Non-GAAP EPS of $7.51.

1. 01

   The company said it reported fourth-quarter revenues of $11.5 Billion, GAAP EPS of $0.87 and Non-GAAP EPS of $1.70 for Q4 2023, and full-year revenues of $45.0 Billion, GAAP EPS of $3.86 and Non-GAAP EPS of $7.51.

2. 02

   Bristol Myers Squibb said worldwide Revlimid revenue declined by 39% for the full year, mainly due to generic erosion and an increase in the number of patients receiving free drug product from the Patient Assistance Foundation. It said worldwide new product portfolio revenue increased 77% to $3.6 billion.

3. 03

   The company set Non-GAAP EPS guidance for 2024 in a range of $7.10 to $7.40 and said it expects total revenues to increase by low single digits. The outlook excludes the impact of pending transactions, including the planned acquisitions of Karuna and RayzeBio.

4. 04

   The company said its Board of Directors declared a quarterly dividend of $0.60 per share in December 2023, an increase of 5.3% over the dividend rate a year earlier. It also approved an additional share repurchase program of $3 billion and said about $5 billion remains available under its total authorization.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.